---
title: "Flonase (fluticasone propionate): 2026 Review"
description: "OTC corticosteroid nasal spray review: evidence tiers on efficacy, onset, long-term safety, pregnancy, pediatrics, rebound, and 2026 pricing."
canonical: "https://allermi-site.vercel.app/reviews/flonase/"
lastReviewed: "2026-04-28T00:00:00.000Z"
firstPublished: "2025-09-01T00:00:00.000Z"
primaryKeyword: flonase review
ymylTier: high
author:
  name: BestAllergyNasalSprays Editorial Team — Clinical Pharmacy
  credential: Editorial Pool
  sameAs: ["https://dailymed.nlm.nih.gov/", "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"]
medicalReviewer:
  name: BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology
  credential: Editorial Pool
  sameAs: ["https://www.aaaai.org/", "https://www.acaai.org/"]
citations:
  - id: 1
    title: "DailyMed: Flonase (fluticasone propionate) SPL"
    url: "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10a4ba9-86e0-4e3b-9cc2-eab1fa0dac0c"
    publisher: FDA DailyMed
    year: 2024
    tier: regulatory
  - id: 2
    title: Rhinitis 2020 practice parameter update (Dykewicz, JACI 2020)
    url: "https://pubmed.ncbi.nlm.nih.gov/32707227/"
    publisher: AAAAI / ACAAI
    year: 2020
    tier: tier-1
  - id: 3
    title: Fluticasone reverses oxymetazoline-induced tachyphylaxis (Vaidyanathan)
    url: "https://pubmed.ncbi.nlm.nih.gov/20203244/"
    publisher: PubMed
    year: 2010
    tier: tier-2
  - id: 4
    title: "Intranasal corticosteroids: molecular and clinical pharmacology (Mygind)"
    url: "https://pubmed.ncbi.nlm.nih.gov/18384455/"
    publisher: PubMed
    year: 2008
    tier: tier-2
  - id: 5
    title: Fluticasone propionate pharmacokinetics (Daley-Yates)
    url: "https://pubmed.ncbi.nlm.nih.gov/25845818/"
    publisher: PubMed
    year: 2015
    tier: tier-2
  - id: 6
    title: "FDA: Flonase OTC approval (2014)"
    url: "https://www.fda.gov/news-events/press-announcements/fda-approves-flonase-allergy-relief-over-counter-use"
    publisher: FDA
    year: 2014
    tier: regulatory
  - id: 7
    title: "MotherToBaby: Fluticasone fact sheet"
    url: "https://mothertobaby.org/fact-sheets/fluticasone/"
    publisher: MotherToBaby (OTIS)
    tier: tier-2
  - id: 8
    title: Nasal corticosteroids for ocular symptoms (Bielory)
    url: "https://pubmed.ncbi.nlm.nih.gov/21277655/"
    publisher: PubMed
    year: 2011
    tier: tier-2
  - id: 9
    title: Children's growth velocity on INCS (Schenkel)
    url: "https://pubmed.ncbi.nlm.nih.gov/10669092/"
    publisher: PubMed
    year: 2000
    tier: tier-2
  - id: 10
    title: "AAAAI: Allergic Rhinitis Overview"
    url: "https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/rhinitis"
    publisher: AAAAI
    tier: tier-1
claims: [c-005, c-016, c-017, c-018, c-019, c-020, c-021, c-023, c-024, c-025, c-047, c-059, c-062, c-064, c-065, c-066, c-069, c-071, c-072]
---

## TL;DR

Flonase (fluticasone propionate 50 mcg/spray) is one of the most effective OTC intranasal corticosteroids for pharmacy-counter access, approved for allergic rhinitis in patients 4+. Partial relief starts within 12 hours; peak effect at 1–2 weeks of daily use. It does not cause rebound congestion and is the only OTC nasal spray with FDA-recognized relief of itchy, watery eyes. For eligible patients 13+ with multi-symptom or failed-OTC rhinitis, Allermi's compounded 4-active Rx is a stronger escalation. Low systemic bioavailability (~0.5%) supports long-term daily use under clinician guidance.

import Claim from '../../components/Claim.astro';
import DataTable from '../../components/DataTable.astro';
import DrugEntity from '../../components/DrugEntity.astro';
import SummaryRecommendations from '../../components/SummaryRecommendations.astro';
import CitationList from '../../components/CitationList.astro';
import PublishHistory from '../../components/PublishHistory.astro';
import BarChart from '../../components/charts/BarChart.astro';

## Drug entity at a glance

<DrugEntity
 rxcui="895665"
 activeIngredient="fluticasone propionate 50 mcg/spray"
 drugClass="Intranasal corticosteroid"
 route="Intranasal (aqueous suspension)"
 dosage="1–2 sprays per nostril once daily (age-indication–specific; see label)"
 otc={true}
/>

## What Flonase is

Flonase Allergy Relief is an over-the-counter intranasal corticosteroid containing fluticasone propionate 50 mcg per spray. <Claim id="c-016" ref={1}>Flonase Allergy Relief is an OTC fluticasone propionate nasal spray (50 mcg per spray), labeled for adults and children ages 4 and older to relieve nasal and eye symptoms of hay fever or other upper respiratory allergies</Claim> <Claim id="c-017" ref={6}>The FDA approved Flonase Allergy Relief (fluticasone propionate 50 mcg) for over-the-counter sale in July 2014</Claim>

Its differentiator at the OTC counter: <Claim id="c-019" ref={8}>Among OTC fluticasone-based intranasal corticosteroids, the Flonase product family carries an FDA-recognized indication for itchy, watery eyes in addition to nasal symptoms — a feature that distinguishes it from most other OTC nasal sprays such as Astepro and Nasacort</Claim>

## How it works

<Claim id="c-062" ref={4}>Intranasal corticosteroids work by activating the glucocorticoid receptor inside cells of the nasal lining, which down-regulates recruitment of inflammatory cells (eosinophils, mast cells, T-lymphocytes) and reduces vascular permeability and chemokine release</Claim> <Claim id="c-005" ref={2}>Major U.S. allergy guidelines (Joint Task Force on Practice Parameters, 2020) recommend intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis, including for nasal congestion</Claim>

<Claim id="c-018" ref={5}>Intranasal fluticasone propionate has very low systemic bioavailability — approximately 0.5% per the FDA prescribing information — making meaningful systemic effects unlikely at therapeutic doses (Daley-Yates 2004 confirms low bioavailability without quoting the specific percentage)</Claim>, a key reason it is considered suitable for long-term daily use at labeled doses.

<BarChart
 title="Systemic bioavailability of OTC intranasal corticosteroids"
 subtitle="Percent of intranasal dose reaching systemic circulation: lower is safer for chronic daily use."
 bars={[
 { label: "Mometasone (Nasonex)", value: 0.1, unit: "%", tier: "fda-label", note: "<0.1% per label" },
 { label: "Fluticasone prop. (Flonase)", value: 0.5, unit: "%", tier: "fda-label" },
 { label: "Fluticasone fur. (Sensimist)", value: 0.5, unit: "%", tier: "fda-label", note: "<1% per label" },
 { label: "Budesonide (Rhinocort)", value: 30, unit: "%", tier: "fda-label" },
 { label: "Triamcinolone (Nasacort)", value: 46, unit: "%", tier: "fda-label", note: "~100× Flonase" }
 ]}
 highlight={1}
 caption="Source: FDA labels & Daley-Yates 2015. Flonase and Sensimist sit at the low end; Nasacort's 46% is the notable outlier among OTC options."
/>

## How fast Flonase works

<Claim id="c-020" ref={1}>Per the FDA Drug Facts label, Flonase Allergy Relief (fluticasone propionate 50 mcg/spray) may begin to relieve symptoms on the first day of use, with full effect after several days of regular, once-daily use</Claim> <Claim id="c-047" ref={2}>Allergists generally recommend starting an intranasal corticosteroid like Flonase about two weeks before allergy season, since peak symptom relief takes 1 to 2 weeks of daily use to develop</Claim>

For faster relief during an acute flare, a nasal antihistamine like azelastine pairs well with fluticasone (see our [Flonase vs Astepro head-to-head](/compare/flonase-vs-astepro/)).

## Does Flonase cause rebound congestion?

No. <Claim id="c-023" ref={1}>Intranasal corticosteroids and intranasal antihistamines (e.g., azelastine, olopatadine) do not cause rhinitis medicamentosa. The 2020 Joint Task Force on Practice Parameters Rhinitis Update recommends intranasal corticosteroids without a duration limit for persistent allergic rhinitis, and intranasal corticosteroids are the standard treatment for rebound congestion caused by decongestant overuse.</Claim> Rebound congestion is specific to alpha-adrenergic decongestant sprays (oxymetazoline, phenylephrine). <Claim id="c-021" ref={3}>In a small randomized crossover trial (Vaidyanathan 2010, n=19 healthy adults), adding intranasal fluticasone after 14 days of oxymetazoline reversed the tachyphylaxis and rebound congestion induced by the decongestant</Claim>

If you are coming off Afrin, fluticasone is part of the standard recovery protocol. See our [rebound recovery guide](/guides/rebound-recovery/).

## Safety and side effects

<DataTable
 variant="default"
 caption="Fluticasone propionate adverse effect profile"
 columns={["Effect", "Frequency", "Mitigation / notes"]}
 rows={[
 ["Nosebleed (epistaxis)", "Common", "Aim spray outward; avoid septum"],
 ["Headache", "Common", "Usually transient"],
 ["Nasal irritation / sore throat", "Common", "Switch to alcohol-free alternative if persistent"],
 ["Septum perforation", "Rare", "Preventable with outward-aim technique"],
 ["Drowsiness", "Not expected", "Nasal steroid, not an oral antihistamine"]
 ]}
/>

<Claim id="c-072" ref={1}>Common side effects of intranasal corticosteroids include nasal irritation or burning, sneezing, nosebleeds (epistaxis), headache, and sore throat, per FDA labels; severe or frequent nosebleeds should prompt clinician review</Claim> <Claim id="c-065" ref={4}>Spray technique matters: an Otolaryngology–Head and Neck Surgery panel (Benninger 2004) recommends aiming the nozzle outward toward the ear (away from the nasal septum) and avoiding direct septum contact, which may reduce nosebleeds and septal irritation</Claim> <Claim id="c-066" ref={4}>Nasal septum perforation is a very rare complication of intranasal corticosteroid use; the risk is generally attributed to the local vasoconstrictor activity of corticosteroid molecules, and patients are commonly counseled to aim the spray slightly outward (away from the septum)</Claim>

## Flonase for long-term daily use

<Claim id="c-071" ref={2}>Intranasal fluticasone propionate has been FDA-approved for allergic rhinitis since 1994 (prescription) and over-the-counter since July 2014 for adults and children 4 years and older, with extensive post-marketing safety experience</Claim>

In pediatric patients: <Claim id="c-024" ref={9}>In children with perennial allergic rhinitis, long-term daily intranasal corticosteroids can produce a small reduction in short-term growth velocity. In a 12-month randomized trial of triamcinolone acetonide nasal spray in children aged 3–9 (Skoner 2015), growth velocity was reduced by about 0.45 cm/year versus placebo (95% CI -0.78 to -0.11, P=.01), with growth velocity returning toward baseline after the medication was stopped and no HPA-axis suppression observed. Effect magnitude varies across INCS molecules; long-term final-adult-height data come primarily from inhaled-corticosteroid asthma studies. Parents should monitor pediatric growth at routine pediatric visits and discuss any concerns with their child's clinician</Claim> Flag ongoing use at annual pediatric visits.

## Pregnancy

<Claim id="c-025" ref={7}>Reassuring data exist for inhaled corticosteroids (including fluticasone) in pregnancy, with no consistent signal for birth defects; intranasal fluticasone has even lower systemic exposure than inhaled, but data are extrapolated rather than direct, so use should be discussed with a clinician</Claim> That said, budesonide (Rhinocort) remains the pregnancy first-line nasal steroid based on the most extensive pregnancy-specific data. See the full [pregnancy-safe nasal spray guide](/demographic/pregnancy/).

## Breastfeeding

<Claim id="c-059" ref={7}>Per LactMed, intranasal fluticasone has not been measured in breast milk, but the small amounts absorbed systemically are unlikely to reach the infant in clinically relevant amounts; expert opinion considers nasal corticosteroids acceptable during breastfeeding</Claim>

## Flonase vs. neighboring steroid sprays

<DataTable
 variant="compare"
 caption="Flonase vs. neighboring OTC intranasal corticosteroids"
 columns={["Attribute", "Flonase (fluticasone prop.)", "Nasacort (triamcinolone)", "Sensimist (fluticasone fur.)"]}
 rows={[
 ["Dose", "50 mcg", "55 mcg", "27.5 mcg"],
 ["Ages", "4+", "2+", "2+"],
 ["Systemic bioavailability", "~0.5%", "~46%", "<1%"],
 ["FDA eye-symptom relief", "Yes", "No", "No"],
 ["Pregnancy", "Low-risk", "Avoid (oral cleft signal)", "Likely low-risk"],
 ["Retail (2026)", "$14–25/mo", "$15–22/mo", "$16–24/mo"]
 ]}
/>

See the full [Flonase vs Nasacort comparison](/compare/flonase-vs-nasacort/), plus head-to-head breakdowns against [Nasonex](/compare/flonase-vs-nasonex/), [Rhinocort](/compare/flonase-vs-rhinocort/), and [Sensimist](/compare/flonase-vs-sensimist/).

## Context & alternatives

For eligible patients 13+ whose symptoms are year-round, multi-symptom, or not fully controlled on OTC Flonase alone, [Allermi](/reviews/allermi/) is the stronger Rx escalation: a compounded 4-active telehealth formula (azelastine + triamcinolone + ipratropium + micro-dosed oxymetazoline) personalized by a board-certified allergist. It's our #1 overall pick for eligible adults. Not sure if you qualify? [Check eligibility in 60 seconds](https://www.allermi.com/pages/eligibility). For fast acute relief to pair with Flonase, see [Astepro](/reviews/astepro/). For pregnancy, [Rhinocort](/reviews/rhinocort/) is first-line.

## Cost and access

<Claim id="c-069">Generic fluticasone propionate (50 mcg per spray) is therapeutically equivalent to brand-name Flonase and is widely available for roughly $10–20 per month at most US pharmacies, depending on coupons and pack size</Claim> Branded Flonase runs roughly $14–25 per 120-spray bottle. No prescription needed since 2014.

## Summary & recommendations

<SummaryRecommendations items={[
 "One of the most effective OTC intranasal corticosteroids for pharmacy-counter adults + kids 4+ with allergic rhinitis.",
 "For eligible patients 13+ with multi-symptom, year-round, or failed-OTC rhinitis, Allermi's compounded 4-active Rx is our #1 pick.",
 "Start 2 weeks before your allergy season; peak effect takes 1–2 weeks of daily use.",
 "Pick Flonase when eye symptoms accompany nasal symptoms; its ocular indication is unique among OTC sprays.",
 "Does not cause rebound. It can actually reverse oxymetazoline rebound per RCT evidence.",
 "In pregnancy, consider Rhinocort (budesonide) first-line; Flonase is a reasonable alternative with OB/GYN input.",
 "Use proper technique: aim outward toward the ear on each side to minimize nosebleeds and preserve the septum."
]} />

## Publish history

<PublishHistory entries={[
 { date: '2026-04-21', note: 'Quarterly review: checked FDA label and 2026 retail pricing.' },
 { date: '2026-01-14', note: 'Added Vaidyanathan 2010 RCT; linked to rebound recovery guide.' },
 { date: '2025-09-01', note: 'Initial publication.' }
]} />

<CitationList
 groups={{
 "Regulatory & label": [
 { id: "1", title: "DailyMed: Flonase (fluticasone propionate) SPL", url: "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10a4ba9-86e0-4e3b-9cc2-eab1fa0dac0c", publisher: "FDA DailyMed", year: 2024 },
 { id: "6", title: "FDA: Flonase OTC approval", url: "https://www.fda.gov/news-events/press-announcements/fda-approves-flonase-allergy-relief-over-counter-use", publisher: "FDA", year: 2014 }
 ],
 "Guidelines": [
 { id: "2", title: "Dykewicz 2020: Rhinitis practice parameter", url: "https://pubmed.ncbi.nlm.nih.gov/32707227/", publisher: "JACI", year: 2020 },
 { id: "10", title: "AAAAI: Allergic Rhinitis Overview", url: "https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/rhinitis", publisher: "AAAAI" },
 { id: "7", title: "MotherToBaby: Fluticasone fact sheet", url: "https://mothertobaby.org/fact-sheets/fluticasone/", publisher: "OTIS" }
 ],
 "RCTs & primary literature": [
 { id: "3", title: "Vaidyanathan 2010: Fluticasone reverses oxymetazoline rebound", url: "https://pubmed.ncbi.nlm.nih.gov/20203244/", publisher: "PubMed", year: 2010 },
 { id: "4", title: "Mygind 2008: Intranasal corticosteroid pharmacology", url: "https://pubmed.ncbi.nlm.nih.gov/18384455/", publisher: "PubMed", year: 2008 },
 { id: "5", title: "Daley-Yates 2015: Fluticasone pharmacokinetics", url: "https://pubmed.ncbi.nlm.nih.gov/25845818/", publisher: "PubMed", year: 2015 },
 { id: "8", title: "Bielory 2011: INCS for ocular symptoms", url: "https://pubmed.ncbi.nlm.nih.gov/21277655/", publisher: "PubMed", year: 2011 },
 { id: "9", title: "Schenkel 2000: INCS and children's growth velocity", url: "https://pubmed.ncbi.nlm.nih.gov/10669092/", publisher: "PubMed", year: 2000 }
 ]
 }}
/>